Suzuki Kazuhiro, Ohtake Nobuaki, Nakata Seiji, Takei Tomoyuki, Matsui Hiroshi, Ono Yoshihiro, Nakazato Haruki, Hasumi Masaru, Koike Hidekazu, Ito Kazuto, Fukabori Yoshitatsu, Kurokawa Kohei, Yamanaka Hidetoshi
Department of Urology, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, Japan 371-8511.
Anticancer Res. 2002 Nov-Dec;22(6B):3507-11.
To investigate the relationship between two common variants (Ser217 and Ala541) of the HPC2/ELAC2 gene and prostate cancer risk in a Japanese population, we performed a case-control study.
Cases and controls consisted of 81 prostate cancer patients with a family history and 106 controls. Ser217 and Ala541 polymorphisms were analyzed by the restriction fragment length polymorphism method.
In controls, 94.5% and 100.0% had wild-type Ser217Ser and Ala541Ala genotypes, respectively. 5.7% of the controls had the Leu217 genotype. No Thr541 genotype was observed in the controls. 92.6% and 97.5% of the cases had the Ser217Ser and Ala541Ala genotypes. No significant differences were observed in the genotypic frequencies between controls and cases. We stratified prostate cancer cases according to the pathological grade (low- or high-grade) or the clinical stage (localized or metastatic). There was no statistical difference between the genotypic frequencies between the groups.
The present study suggested that the common variants in the HPC2/ELAC2 gene play a limited role in the risk of prostate cancer in the Japanese population.
为了研究HPC2/ELAC2基因的两个常见变异（Ser217和Ala541）与日本人群前列腺癌风险之间的关系，我们进行了一项病例对照研究。
病例组和对照组分别由81例有家族史的前列腺癌患者和106例对照组成。采用限制性片段长度多态性方法分析Ser217和Ala541多态性。
在对照组中，分别有94.5%和100.0%的个体具有野生型Ser217Ser和Ala541Ala基因型。5.7%的对照组个体具有Leu217基因型。在对照组中未观察到Thr541基因型。92.6%和97.5%的病例具有Ser217Ser和Ala541Ala基因型。对照组和病例组之间的基因型频率无显著差异。我们根据病理分级（低级别或高级别）或临床分期（局限性或转移性）对前列腺癌病例进行分层。各亚组之间的基因型频率无统计学差异。
本研究表明，HPC2/ELAC2基因的常见变异在日本人群前列腺癌风险中起有限作用。
Zotero 插件